SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it has acquired a series of optimized anti-CD20 monoclonal antibodies from Diversa Corporation .

CAMBRIDGE, Mass., May 11 /PRNewswire-FirstCall/ -- Celunol Corp., a leader in the development of cellulosic ethanol, announced today that members of its management will participate in four upcoming conferences. Carlos A.

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- Diversa Corporation today reported financial results for the quarter and nine months ended September 30, 2006.

SAN DIEGO and LUDWIGSHAFEN, Germany, Feb. 16 /PRN